Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05333497
Other study ID # HeilongjiangUCM
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 18, 2022
Est. completion date February 1, 2023

Study information

Verified date March 2023
Source Heilongjiang University of Chinese Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to study the effect mechanism of programmed flexor-extensor alternating electrical acupiont stimulation on upper limb functional reconstruction after stroke.


Description:

After being informed about the study and potential risks, all patients who meet the inclusion criteria, after signing the informed consent, will be randamized divided into two groups in a blind manner. The patients will undergo a 3-week treatment (6 days per week and 1 day for rest, a total of 18 days of treatment). Those in the control group are treated with conventional flexor-extensor alternating electrical acupiont stimulation, and in the treatment group, programmed stimulation will be adopted (30 minutes, once a day). Besides, data from healthy participants will be collected and processed for reference and control purposes.


Recruitment information / eligibility

Status Completed
Enrollment 84
Est. completion date February 1, 2023
Est. primary completion date April 18, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 35 Years to 75 Years
Eligibility Inclusion Criteria: - Inclusion criteria for patients 1. Meet the diagnostic criteria of stroke; 2. Age: 35 ~75 years old, male and female; 3. Course of disease: 2 weeks to 3 months after stroke, stable vital signs, basically normal cognitive function, can cooperate to complete the test; 4. Manual muscle test (MMT) =2, modified Ashworth (MAS) of paralyzed upper limbs was graded ?~?; 5. BMI =28; 6. No serious heart, lung, kidney and other functional damage and serious underlying diseases, no pain in the affected side of the upper limb joint; 7. The informed consent was signed by the patient and/or his/her family members. Note: Patients who meet the above 7 criteria can be included in this study. - Inclusion criteria for healthy subjects: 1. Those who have been proved to be healthy by physical examination and have no organic lesions or obvious functional diseases; 2. Age: 35 ~75 years old, male and female; 3. No cold, fever, cough, headache and other physical abnormalities during the test; 4. Did not take any excitatory drugs in the past one month, no recent treatment related to experimental content; 5. No history of mental or nervous system; 6. The subject agrees and signs the informed consent. - Exclusion Criteria: 1. Severe cognitive dysfunction, severe aphasia, can not cooperate with the whole treatment or testing process; 2. Patients with serious primary diseases such as heart, lung, kidney, liver and endocrine system; 3. Neurological or musculoskeletal diseases affecting functional recovery before onset; 4. Cerebral stem stroke or bilateral stroke; 5. Patients with severe anxiety, depression, affective disorders, schizophrenia and other serious mental disorders; 6. Examination confirmed by brain tumor, brain trauma, brain parasitic diseases, metabolic disorders, rheumatic heart disease, coronary heart disease and other heart disease with atrial fibrillation caused by cerebral embolism; 7. Patients with skin damage, infection or deformity at the treatment site.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
the fourth programmed generation of low-frequency acupoint electric stimulation therapy instrument
Conventional electrical stimulation does not produce coordinated movement of multiple joints by stimulating several locally generated single ones simultaneously. The stimulation after the improved program, through different time output electrical stimulation on different parts of the muscles or muscle groups, forming the programmed motion. The purpose of this study is to achieve the rehabilitation goal of single joint - multiple joint - extensive movement, promote the coordination recovery of affected limb movement and relieve muscle fatigue.
the fourth generation of low-frequency acupoint electric stimulation therapy instrument
In this study, the instrument of alternate acupoint electrical stimulation of flexor and extensor muscles combines traditional acupoint therapy with modern low-frequency electric stimulation technology, has the advantages of non-invasive and convenient application, and has a good effect on improving the range of motion of joints, relieving spasm, enhancing muscle strength, promoting the recovery of the central nervous system and other aspects.

Locations

Country Name City State
China The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine Harbin Heilongjiang

Sponsors (1)

Lead Sponsor Collaborator
Yang Liu

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other EEG data of healthy controls To record the immediate Alpha, Beta, Delta and Theta bands of the eyes-closed resting state EEG of the healthy controls in a quiet without any interference laboratory. 1 week before the beginning of the whole clinical trail
Other sEMG data of healthy controls Ask them to do the "reaching and retriving" gross movement, recording the real-time sEMG parameters (RMS and MF) of biceps brachii and triceps brachii muscles during the whole process of the motion. Computer software calculates iEMG and MPF values. 1 week before the beginning of the whole clinical trail
Other EEG power spectrum analysis of healthy controls EEG power spectrum analysis is made to evaluate the brain energy state, for better interpreting the movement control strategy of the central nervous system, providing a reference for the prognosis of patients and the curative effect evaluation. 1 week before the beginning of the whole clinical trail
Other sEMG synergy-coherence analysis of healthy controls sEMG synergy-coherence analysis is made to evaluate the degree of muscle coordination, for better interpreting the movement control strategy of the central nervous system, providing a reference for the prognosis of patients and the curative effect evaluation. 1 week before the beginning of the whole clinical trail
Primary EEG data record To record the immediate Alpha, Beta, Delta and Theta bands of the eyes-closed resting state EEG of patients in the two groups 2 hours before the first treatment.
The EmotivEpoc wireless portable EEG device (developed by Neurotechnology Company, USA) is used to collect EEG data.
2 hours before the first treatment
Primary EEG data record To record the immediate Alpha, Beta, Delta and Theta bands of the eyes-closed resting state EEG of patients in the two groups 2 hours after the first treatment.
The EmotivEpoc wireless portable EEG device (developed by Neurotechnology Company, USA) is used to collect EEG data.
2 hours after the first treatment
Primary EEG data record To record the immediate Alpha, Beta, Delta and Theta bands of the eyes-closed resting state EEG of patients in the two groups 2 hours before the last treatment.
The EmotivEpoc wireless portable EEG device (developed by Neurotechnology Company, USA) is used to collect EEG data.
2 hours before the last treatment
Primary EEG data record To record the immediate Alpha, Beta, Delta and Theta bands of the eyes-closed resting state EEG of patients in the two groups 2 hours after the last treatment.
The EmotivEpoc wireless portable EEG device (developed by Neurotechnology Company, USA) is used to collect EEG data.
2 hours after the last treatment
Primary EEG power spectrum analysis EEG power spectrum analysis: EEG data of the four time points as above are preprocessed on the MATLAB platform. And the analysis is used to objectively evaluate the immediate and cumulative effects of different treatment therapies on cerebral cortex activity by Alpha, Beta, Delta and Theta frequency bands. 1 week after all the EEG data is collected
Primary sEMG data record Ask the patients to do the "reaching and retriving" gross movement, recording the real-time sEMG data of RMS (root mean square) and MF (median frequency) 1 hour before the first treatment.
sEMG cosynergive-coherence analysis: The signals are collected with the sEMG device (H4A2L8), developed by ThoughtTechnology Ltd, Canada.
Datas are respectively collected of the biceps brachii and triceps brachii muscles during the whole process of the motion. Computer software calculates iEMG (integral electromyogram) and MPF (mean power frequency) values.
1 hour before the first treatment
Primary sEMG data record Ask the patients to do the "reaching and retriving" gross movement, recording the real-time sEMG data of RMS and MF 1 hour after the first treatment.
sEMG cosynergive-coherence analysis: The signals are collected with the sEMG device (H4A2L8), developed by ThoughtTechnology Ltd, Canada.
Datas are respectively collected of the biceps brachii and triceps brachii muscles during the whole process of the motion. Computer software calculates iEMG and MPF values.
1 hour after the first treatment
Primary sEMG data record Ask the patients to do the "reaching and retriving" gross movement, recording the real-time sEMG data of RMS and MF 1 hour before the last treatment.
sEMG cosynergive-coherence analysis: The signals are collected with the sEMG device (H4A2L8), developed by ThoughtTechnology Ltd, Canada.
Datas are respectively collected of the biceps brachii and triceps brachii muscles during the whole process of the motion. Computer software calculates iEMG and MPF values.
1 hour before the last treatment
Primary sEMG data record Ask the patients to do the "reaching and retriving" gross movement, recording the real-time sEMG data of RMS and MF 1 hour after the last treatment.
sEMG cosynergive-coherence analysis: The signals are collected with the sEMG device (H4A2L8), developed by ThoughtTechnology Ltd, Canada.
Datas are respectively collected of the biceps brachii and triceps brachii muscles during the whole process of the motion. Computer software calculates iEMG and MPF values.
1 hour after the last treatment
Primary sEMG coherence analysis sEMG coherence analysis: Local mean decomposition (LMD) de-noising methods and non-negative matrix decomposition algorithm are used and cosynergive-coherence analysis of the muscle pairs participating in the programmed motion is analyzed, to study the effects of different electrical stimulation methods on the motor coordination and the central control mechanism. 1 week after all the sEMG data is collected
Secondary Scale evaluation--MBI MBI (Modified Barthel Index): A daily functional activity assessment. Normal (100 points). Each activity is rated on a scale of 5 (5 points), with a minimum of 1 (full dependence) and a maximum of 5 (full independence). The higher the level, the more independent the activity is.
MBI score of upper limb is evaluated and SPSS26.0 statistical software is used for analysis. A two-sided test is used in this study, and the significance level is p<0.05. Parametric method is used when data conditions meet parametric conditions; non-parametric method is used when data conditions do not meet time parameter conditions.
3 hours before the whole clinical trail
Secondary Scale evaluation--MBI The same as above. 3 hours after the whole clinical trail
Secondary Scale evaluation--CSS CSS (China Stroke Scale): A neurological deficits assessment. Normal (45 points), Upper limb normal (12 points). Each activity of upper limb is rated on a scale of 7 (0~6 points). The lower the score, the better the situation is.
CSS score of upper limb is evaluated and SPSS26.0 statistical software is used for analysis. A two-sided test is used in this study, and the significance level is P<0.05. Parametric method is used when data conditions meet parametric conditions; non-parametric method is used when data conditions do not meet time parameter conditions.
3 hours before the whole clinical trail
Secondary Scale evaluation--CSS The same as above. 3 hours after the whole clinical trail
Secondary Scale evaluation--FMA FMA (Fugl-Meyer Assessment): A motor function assessment. Normal (226 points), Upper limb normal (66 points, 33 items). The high the score, the better the situation is.
FMA scale of upper limb is evaluated and SPSS26.0 statistical software is used for analysis. A two-sided test is used in this study, and the significance level is P<0.05. Parametric method is used when data conditions meet parametric conditions; non-parametric method is used when data conditions do not meet time parameter conditions.
3 hours before the whole clinical trail
Secondary Scale evaluation--FMA The same as above. 3 hours after the whole clinical trail
Secondary Scale evaluation--MMT MMT (Manual Muscle Testing): A muscle strength assessment. Normal (level 5) with a minimum of 0 (no muscle contraction) and a maximum of 5 (normal, can resist gravity and sufficient resistance). The higher the score, the more normal muscle strength tends to be.
FMA scale of upper limb is evaluated and SPSS26.0 statistical software is used for analysis. A two-sided test is used in this study, and the significance level is P<0.05. Parametric method is used when data conditions meet parametric conditions; non-parametric method is used when data conditions do not meet time parameter conditions.
3 hours before the whole clinical trail
Secondary Scale evaluation--MMT The same as above. 3 hours after the whole clinical trail
Secondary Scale evaluation--Brunnstrom Brunnstrom motor function assessment: A limb function recovery assessment. Normal (level 6) with a minimum of 1 (no movement) and a maximum of 6 (basiclly normal). The higher the level, the better recovery is.
Brunnstrom scale of upper limb is evaluated and SPSS26.0 statistical software is used for analysis. A two-sided test is used in this study, and the significance level is P<0.05. Parametric method is used when data conditions meet parametric conditions; non-parametric method is used when data conditions do not meet time parameter conditions.
3 hours before the whole clinical trail
Secondary Scale evaluation--Brunnstrom The same as above. 3 hours after the whole clinical trail
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05623644 - Multimodal MR Imaging Study on ET and PD Patients Subjected With MRgFUS Thalamotomy
Active, not recruiting NCT03548779 - North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2 N/A
Completed NCT03295786 - Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease Phase 1/Phase 2
Completed NCT03722212 - Early Diagnosis of the GLUT1 Deficiency Syndrome With a Blood Based Test N/A
Recruiting NCT05973929 - Movement Disorders in Multiple Sclerosis Patients
Terminated NCT02823158 - Bilateral Pallidal Stimulation in Patients With Advanced Parkinson's Disease-LATESTIM N/A
Enrolling by invitation NCT01210781 - Target Planning for Placement of DBS-electrodes and Follow-up of the Clinical Efficacy of Stimulation
Enrolling by invitation NCT00355927 - Sedation During Microelectrode Recordings Before Deep Brain Stimulation for Movement Disorders. N/A
Completed NCT00037167 - Effects of Exercise Poles on Older Adults During Exercise Walking Phase 1/Phase 2
Recruiting NCT04784494 - MST for Parkinson's Disease N/A
Terminated NCT03270189 - Effect of the Visual Information Change in Functional Dystonia N/A
Recruiting NCT04061135 - Neurophysiological, Behavioral, and Cognitive Networks in Movement Disorders N/A
Recruiting NCT04176692 - The Effects of Muscle Characteristics on the Control of Shoulder Complex During Functional Movements
Suspended NCT04912115 - Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia Phase 2
Completed NCT00500994 - Neurobiology of Functional Movement Disorder and Non-Epileptic Seizures Early Phase 1
Completed NCT04536987 - Robot Therapy for Rehabilitation of Hand Movement After Stroke Phase 2
Recruiting NCT00001208 - Botulinum Toxin for the Treatment of Involuntary Movement Disorders
Completed NCT02392078 - Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System
Completed NCT00552474 - Deep Brain Stimulation to Treat Symptoms of Parkinson's Disease N/A
Not yet recruiting NCT05032911 - Sensorimotor Control in People With and Without Neck Pain